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Objectives: Electronic medical records (EMR) are increasingly utilized in clini-
cal practice and research, allowing for more efficient availability of rich patient 
records. However, most use of EMR is limited to coded, structured, and adminis-
trative data, while the vast majority of patient information (e.g. disease subtype, 
severity, medical device usage, etc.) is tied up in narrative clinical notes. The chal-
lenge remains in accessing the information in these patient notes. Historically 
this has been done via timely and costly manual chart review, but as the amount 
of EHR data increases exponentially, manual chart review becomes impractical 
and impossible. Advancements in Natural Language Processing (NLP) have dem-
onstrated promising results in combining the capture of additional clinical note 
information with the efficiency of modern informatics. The objective of this study 
is to demonstrate the relevancy and utility of NLP to extract health data from 
EMR in real-world observational studies. MethOds: We conducted a systematic 
review and meta analysis of performance metrics for five (5) NLP-driven projects 
involving oncology, inflammation and medical devices ,which had similar proto-
cols and objectives. We assessed and validated the accuracy of NLP algorithms, 
as well as heterogeneity of accuracy between studies using random effects meta-
analysis (represented by I2 value). Results: A total of 382,523 patients were 
identified using NLP among the 5 studies. Accuracy among the studies ranged 
from 95.2% to 100% (95% CI: 95.1%, 100%), with an I2 value of 95.9% (95% CI: 92.9%, 
97.7%). cOnclusiOns: NLP provide a unique opportunity to extract meaningful 
information from patient-level narrative clinical notes in EMR data sources with 
high degree of accuracy. This provides additional rich sources of data from narra-
tive clinical notes, that are otherwise not easily available, to support epidemiology 
and other real-world observational studies.
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Methotdological difficulties of coMPliance analyses Based on 
Real-WoRld data
Andriska P, Komáromi T, Frigyesy R, Salfer B
Healthware Consulting Ltd., Budapest, Hungary
Objectives: Regarding compliance analysis numerous ratios can be found in 
international scientific literature with simpler or more complex methodology. In 
our analysis we tend to reveal, that choosing an adequate ratio is not sufficient 
itself, it is essential to know the difficulties and pitfalls of the data management 
and methodology to the objective assessment of the chosen ratio. The chief aim 
of our study to demonstrate factors in course of practical examples, which may 
substantially influence the results and the right conclusions, if these factors are 
modified. MethOds: The analysis is based on prescription refilling’s data of 
database of the Hungarian Health Fund in the field of the following indications: 
diabetes, COPD, oncology. From the ratios available in scientific literature, the PDC 
(Proportion of Days Covered) was chosen. The following aspects were considered 
as influencing factors: patient inclusion criteria (index date, time frame, criteria 
of refillings); DDD (WHO, SPC or real-world dosage to DOT); Gap (period without 
medication supply). A basic setting was established to calculate PDC ratio, then 
after changing each above specified parameters one by one (ceteris paribus), the 
ratio was recalculated. Results: The PDC ratio shows huge variability recalcu-
lated by the different values of each parameters. Even more than 20% difference 
can be observed after modifying the gap (strict 1-day or permissive 30-day), or 
applying the SPC dosage instead of WHO DDD. In course of modifying the patient 
inclusion criteria both patient numbers and the ratio also show significant differ-
ences. cOnclusiOns: Based on the results it may be concluded, that no general 
best practice can be observed, all settings have both advantages and limitations. 
It may be worth choosing the key parameters considering the specialties of each 
indications in order to draw conclusions as correct as possible with the focus of 
the original aim of the study.
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Objectives: Generic comorbidity measures developed to predict mortality and/
or healthcare costs are often used as adjustment covariates in observational stud-
ies comparing health expenditures between different therapeutic strategies. The 
objective of this review is to identify available measures, and assess their perfor-
mance for prediction of economic outcomes using large longitudinal patient data-
bases. MethOds: We conducted a comprehensive literature search in MEDLINE, 
until April 2015. All methodological papers describing a new comorbidity measure 
or assessing their ability to predict economic outcomes using administrative data or 
electronic medical records were selected. We search for additional studies through 
references lists of selected articles. We extracted information on the conditions 
for using each index and predictive performance. Results: 323 abstracts were 
identified during the search in MEDLINE and 25 full papers were reviewed. Eleven 
comorbidity measures and seven comparative studies were found. Four comorbid-
ity measures were single cumulative weighted scores: two were diagnosis-based 
indexes developed using large administrative health databases and two others were 
medication-based indexes developed using pharmacy data. Two comorbidity meas-
urement systems consisted in classifying patients in mutually exclusive groups 
defined based on diagnosis and clinical or economical characteristics. Others were 
simple counts of diseases. All measures were based on a list of diseases pre-selected 
by clinicians, except for the Ambulatory Clinical Groups System (ACG). Five meas-
ures were adapted for use with ICD-9-CM and ICD-10 classifications. Hierarchical 
Cost Groups (HCC-CMS) and Quality and Outcome Framework (QOF) showed the 
highest predictive ability in three comparative studies. ACG was the best predictor 
in one study and the second one in three other analyses. cOnclusiOns: HCC-
CMS and QOF were reported to have the best predictive performance. However 
most comparative studies included a limited number of comorbidity measures. 
containing at least one product and one adverse event keyword were collected, de-
identified, and standardized using a vernacular to MedDRA dictionary. Posts were 
classified as resembling an adverse event report (Proto-AEs) or simply discussing 
a product (Mention). Results: There were a total of 1,410,819 posts categorized 
as Proto-AEs, 265,838 (19%) from Facebook and 1,144,981 (81%) from Twitter. The 
top 10 products accounted for 940,666 (67%) of the total Proto-AEs in Facebook and 
Twitter combined. The top 25 accounted for 1,180,040 (84%), the top 50 for 1,285,836 
(91%), and the top 100 for 1,245,010 (95%) of the total Proto-AEs. The top 10 products 
(diphenhydramine, flu vaccine, dextroamphetamine, codeine, morphine, ibuprofen, 
alprazolam, acetaminophen, oxycodone, and zolpidem) were comprised of six con-
trolled substances, three over-the-counter (OTC) products, and one class of vaccine. 
Of the top 50 products, controlled substances accounted for 32%, OTC products for 
24%, and vaccines for 10%. cOnclusiOns: Review of publically available data over 
the past two years from two popular social media sites, Facebook and Twitter, offers 
a high number of potential adverse events (Proto-AEs) for further evaluation. Social 
listening may be potentially valuable as a supplement to traditional pharmacovigi-
lance practices, particularly for controlled substances, over-the-counter products, 
and vaccines. These initial findings warrant more research and a closer inspection 
as to the nature of these posts.
PRM55
hunting foR RandoMised contRolled tRials (Rcts): a coMPaRison of 
seaRch filteRs designed to identify Rcts
Steeves S, Buchanan-Hughes AM, Evans J, Leonard S
Costello Medical Consulting Ltd, Cambridge, UK
Objectives: There are a number of search filters designed to identify studies 
with particular study designs in electronic databases. This study compared three 
filters for identifying randomised controlled trials (RCTs). MethOds: Searches 
were conducted on 15thJune 2015 in the Ovid MEDLINE and MEDLINE In-process 
databases using The Cochrane Highly Sensitive Search Strategy for Identifying 
Randomized Trials in MEDLINE, the SIGN Randomised Controlled Trials MEDLINE 
filter and the BMJ MEDLINE Randomised Controlled Trial Strategy. Differences were 
explored by reviewing samples of records uniquely identified by each filter. For 
comparison, a sample of articles returned by all three filters was also reviewed. 
To estimate the sensitivity of each filter, the detection of 39 publications of RCTs 
included in a randomly-selected Cochrane Collaboration systematic literature 
review (SLR) was tested. Results: 476,551 records were identified by all three 
filters. From a sample of 384 records, 230 were RCTs and 18 were SLRs, meta-
analyses or pooled analyses of RCTs. 1,000,716 records were uniquely identified 
by the Cochrane filter; of 400 records sampled , 0 were RCTs and 3 were SLRs 
or meta-analyses of RCTs. 500,127 articles were uniquely identified by the SIGN 
filter; of 386 records sampled, 8 were RCTs and 1 was a meta-analysis of RCTs. 
84,938 records were uniquely identified by the BMJ filter; of 400 records sampled, 
6 were RCTs and 5 were SLRs or meta-analyses of RCTs. 39/39, 38/39 and 37/39 of 
the Cochrane review publications were identified by the Cochrane, SIGN and BMJ 
filters, respectively. The publication missed by the SIGN filter was not the same as 
the 2 missed by the BMJ filter. cOnclusiOns: All filters failed to identify at least 
some RCTs, SLRs or meta-analyses of RCTs. Differences between filters, including 
the publications uniquely identified by each, should be considered when selecting 
filters for use in literature reviews.
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indiRect tReatMent coMPaRison (itc) to deMonstRate the utility of 
oncolitBank: an oncology liteRatuRe RegistRy
Gala S, Shah A, Nanavaty M, Mwamburi M
Market Access Solutions LLC, Raritan, NJ, USA
Objectives: OncoLitBank is a registry of published oncology trials and Health 
Technology Assessments aimed to help provide a platform for secondary data 
analytics in the field of oncology. To demonstrate the utility and functionality of 
OncoLitBank, we conducted a basic indirect treatment comparison (ITC) between 
gemcitabine/nab-paclitaxel (GemNpac) and gemcitabine/capecitabine(GemCap) 
combinations which were each tested against gemcitabine but not against 
each other for treatment of metastatic pancreatic cancer. MethOds: Using 
OncoLitBank, data for metastatic pancreatic cancer were filtered for treatment-
comparator arms of interest by using built-in interactive features. Two phase III 
randomized controlled trials (RCTs) comparing GemCap vs Gem, while 1 RCT 
comparing GemNpac vs Gem were included for the ITC. Data on overall response 
rate (ORR), 1-year survival, overall survival (OS), progression-free survival (PFS), 
and grade 3-4 adverse events (AEs) were pooled for the 2 RCTs comparing GemCap 
vs Gem using RevMan 5.0. Pooled risk ratios (RRs) and mean differences (MD) 
for the 2 studies were derived for dichotomous and continuous outcome vari-
ables respectively and compared to the single RCT that evaluated GemNpac vs 
Gem to derive the ITC RRs and MDs using the Canadian Agency for Drugs and 
Technologies in Health (CADTH) ITC application which employs Bucher et al. 
(1997) method. Results: The use of OncoLitBank was successful and eliminated 
the need to conduct a new systematic review to perform the ITC leading to a 
quick turn-around of tasks at hand. Results demonstrated that GemNpac was 
not superior to GemCap in ORR, 1-year survival, OS, PFS and grade 3-4 AEs, as 
no significant differences was detected. cOnclusiOns: OncoLitBank provides 
users with a robust data platform that can be easily used for systematic reviews, 
conduct meta-analyses through direct orindirect comparisons, inform economic 
models, landscape analyses, value dossiers, create target product profiles and 
value development plans.
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finalized with input from principal investigators. Results: More than 2900 publica-
tions and 300 websites were screened, and 16 registries, 17 cohort studies and 43 data-
bases were reviewed. Nine data sources from seven countries were recommended, 
of which six complementary sources were included: Get With The Guidelines-Stroke 
in the USA (an in-hospital database including about 1600 hospitals); National Stroke 
Registry in China (132 hospitals); Fukuoka Stroke Registry in Japan (seven stroke 
centres); Clinical Research Centre for Stroke – 5thDivision Registry in South Korea 
(12 stroke centres); Riks-Stroke in Sweden (all Swedish hospitals admitting patients 
with acute stroke); and Erlangen Stroke Registry in Germany (Erlanger community). 
Based on a globally agreed study design concept, protocols for each data source have 
been developed locally and are now being implemented. cOnclusiOns: The ARES 
programme will provide global, observational data from contemporary populations 
with mild stroke/TIA in real-world clinical practice. Studies will be presented individu-
ally owing to differences in the nature of the data sources.
PRM63
health technology assessMent needs infoRMation technology: the 
exPeRience fRoM the fiRst italian study on the da vinci suRgical 
RoBot
Manetti S1, Palla I1, Freschi C2, Cuschieri A3, Turchetti G1
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Objectives: Health Technology Assessment of innovative biomedical devices still 
requires the effort to introduce dedicated Information Technology tools able to 
support the implementation of the evaluation process. The aim of the study was 
to systematize the collection, the management and the analysis of large volumes 
of multidimensional data in order to optimally conduct an HTA study of emerg-
ing technologies. MethOds: We designed a relational database, subsequently we 
developed and implemented a centralized, web-based user-friendly data entry for 
Case Report Form (CRF) data collection. (i) The development of User Interface (UI), 
(ii) data anonymization, (iii) differentiate accesses, (iv) automated quality control 
checks for data entry, (v) appropriate system tables to make data entry uniform, and 
(vi) the possibility of creating final reports were addressed. In the data extraction 
phase, we used MySQL computer languages and combined PHP and HTML codes. 
Knowledge Discovery in Data process was implemented with different software 
and programming languages for automation of the data collection, extraction and 
analysis. Results: The IT tools have been applied to the first multicenter prospec-
tive Italian study of HTA on the da Vinci surgical system, obtaining meaningful end 
points in terms of costs and clinical outcomes. The study involved the enrolment of 
699 patients from the 8 Italian Teaching Hospitals in the period 2011-2014. Patients 
were enrolled and prospectively evaluated from the preoperative work-up till six 
months after the discharge. cOnclusiOns: The IT tools developed allow research-
ers to more efficiently and effectively manage large volumes of various source of 
HTA data, enhancing data quality from storage to processing. The database design 
could be empowered and readjusted for other HTA studies in near future and the 
entire approach generalized. In the immature field of HTA of innovative biomedical 
devices, this example of application could promote the automation of the imple-
mentation process of HTA.
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Objectives: The primary objective is to describe how patients with advanced STS 
are managed in France. The secondary objectives are to describe the epidemiologi-
cal characteristics, the diagnostic procedures as well as the therapeutic strategy for 
the management of patients with STS. MethOds: This observational, retrospective 
and national study will use the patient databases of the European CONTICANET 
“CONnective TIssue Cancer NETwork” network and of the French networks: RRePS 
and NetSarc(Pathological and Clinical Reference Networks for Soft Tissues and 
Visceral Sarcomas) . All the data collected in these networks and compiled in the 
“Sarcoma clinicobiological database” will allow good national representativity of 
STS. The study period was defined to reflect the current situation in terms of diagno-
sis and disease management in France. Results: The European database currently 
contains data from 12,485 patients (pts) registered by the French Sarcoma Group 
centers with 9,736 soft tissues and visceral sarcomas. Data from STS patients, who 
were diagnosed between 2012 and 2013, will be extracted from the Conticabase 
database. Part of these data will be “chained” with the shared database from the 
French networks RRePS (24,000 pts) and NetSarc (28,000 pts). Results are expected at 
the end of 2015. cOnclusiOns: This pharmacoepidemiological study shows how 
useful high-quality medical databases are to study rare diseases and their manage-
ment in real life. This study is carried out as part of a public/private partnership.
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Objectives: Due to high prevalence of socially significant chronic diseases among 
children the introduction of information technologies in the process of interac-
tion between doctor and patient is important. The aim: to analyze the prospects 
of the development of remote monitoring systems, to identify their shortcomings 
and to propose solutions. MethOds: The review had included 36 publications, 1 
meta-analysis concerning telemedicine from 2001 to 2014 y. In the evaluated studies 
the following questions were explored: • research of social and economic aspects of 
The updated version of Charlson Comorbidity Index (CCI), for predicting resource 
utilisation, was never considered in such studies.
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Objectives: The randomized clinical trials (RCT), as gold standard for evidence-
based medicine, have a number of shortcomings, and their results do not fully 
reflect actual clinical practice. In cases where RCTs are difficult to conduct because 
of ethical or other aspects, data bases of clinical cases - medical registries are used 
to determine the effectiveness and safety of any medical intervention in long-
term observation. Due to heterogeneity of clinical symptoms in different groups 
of patients with bronchial asthma (BA), to assess the efficacy and safety of treat-
ment of severe persistent uncontrolled asthma in the real clinical practice, the best 
practice is to use a long-term clinical monitoring. Aim - to create patient registry 
for children and adolescents with severe persistent uncontrolled BA. MethOds: 
By experts of center in the result of system work software was created. It was shell 
for management of database of clinical cases – patient registry of children with 
uncontrolled severe persistent BA, who received Omalizumab as addition to basis 
therapy. Results: The database included information about 64 children (62.5% 
boys) from 6 to 17 y 11 mo (mean age 12.9 y) with severe persistent uncontrolled 
BA, who received / receive (31 patients, 70.9% boys) bioengineered treatment (dura-
tion of treatment from 1 till 70 mo). During the analyzed period of treatment safety 
of Omalizumab was confirmed: more than 5384 injections were conducted. Local 
adverse events were registered at frequency of 1/100 and were manifested as light 
redness, induration and light edema, were realized in 1-1.5 days after Omalizumab 
administration. Local allergic reactions such as rash were observed in two patients 
and were stopped by antihistamines cOnclusiOns: The patient registry will help 
in solving problems as epidemiological, and in order to achieve optimal endpoints 
for monitoring and analysis of efficacy and safety of innovative high-tech medica-
tions and approaches which have been used previously for long time.
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the nationWide osMed health-dB dataBase. a tool to suPPoRt 
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Objectives: Since 2012, the Italian Medicines Agency (AIFA-Agenzia Italiana del 
Farmaco), with the cooperation of CliCon, has been providing and updating the 
OsMed Health-DB Database, a nationwide standardized monitoring system to pro-
vide analyses, reports, and trends on appropriateness of medicines’ use and medica-
tion persistence, to inform decision-makers in order to improve health outcomes 
and to avoid wasting of health-care resources MethOds: The OsMed Health-DB 
Database has two main components with distinct but complementary functions: a 
data-warehouse, a repository containing the integrated demographic, pharmaceuti-
cal and hospital discharges administrative data kept by Local Health Units (LHUs) 
and Regional Health Units (RHUs) and a dashboard, a set of performance indicators, 
with updates scheduled every six months, evaluating the prescription adherence 
to preset standards of some chronic pathologies at the local, regional, and national 
level. In 2014, 36 LHUs and 5 RHUs provided data, covering all Italian Regions and 
the data-warehouse stored information of about 30 million patients (almost the 
50.0% of the entire Italian population). Results: The 2014 OsMed Report reported 
the trend of 34 indicators on appropriateness and adherence of 10 chronic diseases: 
hypertension, hypercholesterolemia, diabetes mellitus, COPD, osteoporosis, depres-
sion, ulcers and esophagitis, anemia, psoriasis and rheumatoid arthritis. The average 
age of the LHU sample resulted 44.0 years versus 43.7 years of the Italian popula-
tion. The percentage of males resulted 48.5%, in accordance with the national data 
available. Medication persistence rate for all studied diseases averaged 43.3%, with a 
range of 13.9% of respiratory system drugs and 62.2% of anti-diabetic drugs. Results 
will be reported on “National Report on medicines use in Italy” available at AIFA 
website. cOnclusiOns: Findings from the OsMed Health-DB Database highlighted 
that the majority of indicators is changing toward appropriateness and adherence. 
These findings prove that continuous monitoring of appropriateness and adherence 
is a driver for improving real-world use of medicines.
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Objectives: Patients with mild stroke or transient ischaemic attack (TIA) are at 
high risk of recurrent stroke and other cardiovascular events. The Assessment of 
Real-world Evidence in Stroke/TIA (ARES) programme aims to characterize the 
management and outcomes of patients with mild stroke/TIA in real-world clinical 
practice using the most suitable data sources. MethOds: In an initial Systematic 
Understanding of Real-world Evidence (SURE) assessment, suitable data sources 
(cohorts, registries and databases) were identified and characterized by systematic 
literature and web searches supplemented with e-mail and telephone contact. Data 
sources were recommended if they were active, representative, accessible, recorded 
National Institutes of Health Stroke Scale (NIHSS) scores or ABCD2 scores, and 
reported health resource utilization, ischaemic events and death during follow-up of 
at least 90 days (either direct or via linkage). The programme of included studies was 
